Camlin Fine Sciences Limited (IN:CAMLINFINE)
:CAMLINFINE
Want to see IN:CAMLINFINE full AI Analyst Report?
Top Page
Camlin Fine Sciences Limited
(CAMLINFINE)
Select Model
Select Model
Rating:45Neutral
Price Target:
₹118.00
▼(-18.23% Downside)
Action:ReiteratedDate:04/24/26
The score is primarily held back by weak financial performance, driven by ongoing losses and worsening cash flow (negative free cash flow) despite modest revenue growth. Technical signals also remain bearish with the price below key longer-term moving averages and a negative MACD. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
B2B specialty-chemicals revenue model
Camlin’s B2B model supplies specialty ingredients and additives to food, beverage and industrial customers. This creates recurring, contract-driven demand tied to manufacturing needs, supporting more predictable revenue streams and durable customer relationships over months.
Negative Factors
Sustained negative profitability
The company has posted negative net income for consecutive years and a -8.34% net margin in the latest period. Persistent losses erode retained earnings, constrain reinvestment, hurt return metrics, and increase reliance on external financing or material margin improvement to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
B2B specialty-chemicals revenue model
Camlin’s B2B model supplies specialty ingredients and additives to food, beverage and industrial customers. This creates recurring, contract-driven demand tied to manufacturing needs, supporting more predictable revenue streams and durable customer relationships over months.
Read all positive factors
Camlin Fine Sciences Limited (CAMLINFINE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹24.39B
Dividend YieldN/A
Average Volume (3M)39.05K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth7.50%
EPS Growth74.18%
CountryIN
Employees624
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.25
Shares Outstanding192,091,610
10 Day Avg. Volume26,894
30 Day Avg. Volume39,045
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)3.33
Price to Sales (P/S)1.80
P/FCF Ratio-190.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹170.00Price Target Upside17.81% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)10.9
Revenue Forecast (FY)₹21.16B
Camlin Fine Sciences Limited Business Overview & Revenue Model
Company Description
Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemical, ingredients, and additive blend products in India and internationally. It offers shelf-life solut...
How the Company Makes Money
Camlin Fine Sciences makes money by manufacturing and selling specialty chemical ingredients and additives to business customers (B2B). Its core revenue model is product sales across its ingredient and additive portfolio—particularly antioxidants ...
Camlin Fine Sciences Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.31B | 16.67B | 15.95B | 16.82B | 14.04B | 11.81B |
| Gross Profit | 9.07B | 7.78B | 6.58B | 8.41B | 6.34B | 5.77B |
| EBITDA | 3.89B | 1.95B | 487.60M | 1.84B | 1.79B | 1.89B |
| Net Income | -292.05M | -1.39B | -927.53M | 521.06M | 606.78M | 509.63M |
Balance Sheet | ||||||
| Total Assets | 20.37B | 20.24B | 19.52B | 20.60B | 18.00B | 14.82B |
| Cash, Cash Equivalents and Short-Term Investments | 1.63B | 1.92B | 812.28M | 951.90M | 1.29B | 1.21B |
| Total Debt | 6.72B | 6.81B | 6.83B | 8.01B | 6.46B | 5.50B |
| Total Liabilities | 11.77B | 11.49B | 10.95B | 12.36B | 10.35B | 7.68B |
| Stockholders Equity | 8.90B | 9.02B | 8.65B | 8.19B | 7.48B | 6.43B |
Cash Flow | ||||||
| Free Cash Flow | 374.83M | -157.24M | 784.06M | -934.11M | -683.40M | 335.07M |
| Operating Cash Flow | 671.39M | 267.23M | 1.39B | 508.98M | 1.45B | 1.17B |
| Investing Cash Flow | -160.19M | -753.50M | -664.98M | -1.25B | -2.49B | -1.33B |
| Financing Cash Flow | -677.54M | 724.43M | -859.72M | 596.58M | 1.36B | 386.27M |
Camlin Fine Sciences Limited Technical Analysis
Negative
144.30
Price Trends
133.81
Negative
142.53
Negative
186.38
Negative
Market Momentum
-7.87
Negative
38.27
Neutral
61.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Negative. The current price of 144.3 is above the 20-day moving average (MA) of 109.52, above the 50-day MA of 133.81, and below the 200-day MA of 186.38, indicating a bearish trend. The MACD of -7.87 indicates Negative momentum. The RSI at 38.27 is Neutral, neither overbought nor oversold. The STOCH value of 61.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAMLINFINE.
Camlin Fine Sciences Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹30.18B | 116.03 | ― | 0.10% | -13.24% | 35.53% | |
69 Neutral | ₹43.15B | 29.53 | ― | 0.97% | -5.17% | -22.34% | |
65 Neutral | ₹38.94B | 19.90 | ― | 1.70% | 13.07% | 14.46% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹43.05B | 211.46 | ― | 0.09% | 5.66% | -60.04% | |
58 Neutral | ₹26.51B | 14.05 | ― | 0.09% | 15.19% | 9.27% | |
45 Neutral | ₹24.39B | -19.42 | ― | ― | 7.50% | 74.18% |
* Basic Materials Sector Average
IN:CAMLINFINE
Camlin Fine Sciences Limited
126.97
-40.13
-24.02%
IN:ADVENZYMES
Advanced Enzyme Technologies Ltd
347.95
69.83
25.11%
IN:BALAMINES
Balaji Amines Limited
1,331.85
76.80
6.12%
IN:NEOGEN
Neogen Chemicals Ltd.
1,631.95
129.11
8.59%
IN:PREMEXPLN
Premier Explosives Limited
561.30
150.94
36.78%
IN:ROSSARI
Rossari Biotech Ltd
478.75
-188.69
-28.27%
Camlin Fine Sciences Limited Corporate Events
Camlin Fine Sciences Seeks Shareholder Nod to Raise Authorised Capital via Postal Ballot
Apr 7, 2026
Camlin Fine Sciences has initiated a postal ballot process to seek shareholder approval for increasing its authorised share capital from ₹21.5 crore to ₹25 crore, through an expansion in the number of equity shares of ₹1 each. Th...
Camlin Fine Sciences’ European Subsidiary Placed in Judicial Liquidation by Italian Court
Mar 18, 2026
Camlin Fine Sciences has disclosed that the Ordinary Court of Ravenna in Italy has opened judicial liquidation proceedings for its wholly owned subsidiary CFS Europe S.p.A., following an appeal by the subsidiary’s Board of Statutory Auditors...
Camlin Fine Sciences Delays Vinpai Tender Filing, Keeps Listing Plan Intact
Mar 16, 2026
Camlin Fine Sciences has updated investors on the timetable for its mandatory tender offer for the remaining shares of French company Vinpai, after previously acquiring a controlling 83.82% stake through a block deal and conversion of convertible ...
Camlin Fine Sciences Faces GST Demand but Sees No Material Impact
Mar 16, 2026
Camlin Fine Sciences has disclosed that it received an order from the Office of the Commissioner of CGST Central Excise, Palghar, demanding reversal of allegedly ineligible input tax credit of Rs 23.54 crore for FY 2019-20 to FY 2022-23. The orde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.